Medical Affairs & Social Media in Rare Disease

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Medical’s Road Map for Social Media Success in Rare Disease Segment: Structure and Activities”

STUDY OVERVIEW

With a relatively small target audience, Medical Affairs groups within Rare Disease organizations encounter distinctive challenges in establishing meaningful connections. Recognizing the potential of social media in engaging with crucial stakeholders such as healthcare providers, thought leaders, patients, and digital opinion leaders, forward-looking Rare Disease companies are seizing the opportunity to excel.

However, to effectively engage their target audience, Medical Affairs leaders should lay a solid foundation by establishing the right organizational structure and engaging in relevant activities.

Best Practices, LLC undertook benchmarking research to develop a roadmap for Medical Affairs' social media success in Rare Disease segment. The study examines the optimal structure for Medical Affairs groups within Rare Disease organizations to engage in social media initiatives and emphasizes key social media activities to effectively educate the market.

The research provides benchmarks around social media account quantity, separation of accounts, share of account ownership, medical affairs involvement, vendor utilization, social media platforms utilized, target audiences, social media goals, proactive vs. reactive interaction proportions, and proactive social media activities for medical.

KEY TOPICS

Social Media Structure
Social Media Management
Social Media Activities

KEY METRICS

What is the geographic span of responsibility of benchmarked Rare Disease organizations?
Do Rare Disease organizations have a single social media account or multiple?
What is the range of multiple social media accounts?
Please indicate how the organization’s social media accounts are separated
To what degree is the Medical Affairs function involved in social media initiatives at Rare Disease organizations?
To what degree does Medical Affairs share social media accounts with other groups in the organization?
Do Rare Disease Medical Affairs groups partner with third party vendors to support or drive social media activities?
Please indicate the social media platforms which are utilized by Rare Disease Medical Affairs groups
Which groups are target audiences for Medical’s social media activities?
Which goals are priorities for Medical Affairs group’s social media efforts?
What percentage of Medical Affairs’ social media engagements are currently proactive vs. reactive?
Please specify the proactive activities Rare Disease Medical Affairs groups perform through their social media accounts
Please indicate how effective each social media platform is for each of the listed proactive activities
Please rate the effectiveness of proactive social media activities in engaging each target audience

SAMPLE KEY FINDINGS

Social Media Initiatives: While just 14% of Medical groups from TBC Ex. Rare Disease companies operate or lead social media accounts, 57% support social media initiatives. Heavy support by Medical in Rare (60%).

METHODOLOGY

Best Practices, LLC engaged 48 Medical leaders from 36 biopharma companies in this benchmarking research. For Rare Disease therapeutic area-specific insights, two segments were investigated in this study: Responses from 11 social media leaders at 8 Rare Disease organizations were analyzed against the rest of the total benchmark class.

Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Medical; Biopharmaceutical; Health Care; Consulting

Companies Profiled:
AbbVie; Avidity Biosciences; AstraZeneca; Baxter Healthcare; Bayer; BIAL; Boehringer Ingelheim; Boston Scientific; Complete HealthVizion | An IPG Health Company; Domp�; DURECT Corporation; Eisai; Elevation Oncology; EMD Serono; Ethicon Endo-Surgery Inc.; Gossamer Bio; Grifols; Hoya Vision Care; Janssen; LEO Pharma; MedVal Scientific Information Services; Merck KGaA; Merck Sharp & Dohme; Merz Pharma; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novartis Oncology; Novo Nordisk; PRECISIONscientia; Servier; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Medical’s Road Map for Social Media Success in Rare Disease Segment: Structure and Activities

ID: 5761

Features:

Pages/Slides: 34

Published: 2023

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B6140D43AB95EAB3002589B100238020
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medicals-road-map-for-social-media-success-rare-disease-structure-activities?opendocument
18
19opendocument
2044.220.247.152
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB